Intra-Cellular Therapies, Inc. (ITCI) has 159 open-market insider trades by 18 insiders since 2014. The most active filer is Lawrence J. Hineline, CFO & VP.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Christopher D. Alafi | Dir | — | 19 | $50.0M | 2021-05-28 |
| Rory B. Riggs | Dir | — | 4 | $29.2M | 2025-04-02 |
| Lawrence J. Hineline | CFOVP | — | 23 | $25.1M | 2024-03-11 |
| Sharon Mates | CEOChairman | — | 23 | $24.9M | 2025-04-02 |
| Michael Halstead | Pres | — | 21 | $23.6M | 2025-04-02 |
| Mark Neumann | CCOVP | — | 16 | $20.7M | 2025-04-02 |
| Joel S. Marcus | Dir | — | 12 | $17.1M | 2025-04-02 |
| Moshe Alafi | 10% Owner | — | 9 | $11.5M | 2017-10-02 |
| ALAFI Capital Co. LLC | 10% Owner | — | 7 | $5.8M | 2017-10-02 |
| Robert L. van Nostrand | Dir | — | 2 | $4.6M | 2025-04-02 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Sharon Mates | CEO & Chairman | Sell | $15.4M | 2024-12-04 |
| Michael Halstead | President | Sell | $7.4M | 2024-11-12 |
| Sharon Mates | CEO & Chairman | Sell | $9.8M | 2024-08-29 |
| Sharon Mates | CEO & Chairman | Sell | $14.1M | 2024-08-26 |
| Sharon Mates | CEO & Chairman | Sell | $18.0M | 2024-08-21 |
| Mark Neumann | CCO & VP | Sell | $2.8M |
Companies that share insiders with ITCI, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2024-08-16 |
| Rory B. Riggs | Director | Sell | $674K | 2024-06-24 |
| Robert L. van Nostrand | Director | Sell | $3.0M | 2024-06-18 |
| Mark Neumann | CCO & VP | Sell | $2.7M | 2024-03-07 |
| Suresh K. Durgam | VP | Sell | $1.3M | 2024-03-07 |
| Sharon Mates | CEO & Chairman +1 | Sell | $8.1M | 2024-03-07 |
| Michael Halstead | CLO & VP | Sell | $2.7M | 2024-03-07 |
| Lawrence J. Hineline | CFO & VP | Sell | $3.0M | 2024-03-07 |
| Robert L. van Nostrand | Director | Sell | $2.9M | 2024-02-27 |
| Suresh K. Durgam | VP | Sell | $382K | 2024-02-26 |